Skip to main content
Erschienen in: Indian Journal of Pediatrics 2/2018

09.11.2017 | Original Article

Socio-demographic Profile and Economic Burden of Treatment of Transfusion Dependent Thalassemia

verfasst von: Amita Moirangthem, Shubha R. Phadke

Erschienen in: Indian Journal of Pediatrics | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

To compile the socio-demographic profile and estimate the economic burden of transfusion dependent thalassemia.

Methods

This cross-sectional descriptive study was conducted at a tertiary care hospital in north India. Transfusion dependent thalassemia patients on regular blood transfusion for at least a year were selected. Thalassemia diagnosis was based on HPLC and/or mutation analysis results. Clinical and laboratory parameters were collected from electronic health records. Information regarding socio-economic profile and costs incurred, including indirect costs were collected by interviewing patients’ guardians. The data was analyzed as a whole cohort and also in subgroups based on age.

Results

The data of 261 patients with a median age of 127 mo was collected. The median age at diagnosis was 9.8 mo. The total treatment expenses of a patient per year ranged from US$ 629 (INR 41,514) to US$ 2300 (INR 151,800), in the different age groups, at an average of US$ 1135 (INR 74,948). More than half (53%) of this was spent on medications. On an average, 38.8% of the family income was spent on the treatment of a thalassemia patient annually. Only 19 of 262 cases had an average pre-BT Hb ≥ 9 g/dl and serum ferritin ≤1500 ng/dl.

Conclusions

The treatment for transfusion dependent thalassemia is costly and mostly borne by the families in India. This study provides a realistic magnitude of this burden and will be useful in planning a thalassemia management program at the state or national level.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Verma IC, Saxena R, Kohli S. Past, present & future scenario of thalassemic care & control in India. Indian J Med Res. 2011;134:507–21.PubMedPubMedCentral Verma IC, Saxena R, Kohli S. Past, present & future scenario of thalassemic care & control in India. Indian J Med Res. 2011;134:507–21.PubMedPubMedCentral
3.
Zurück zum Zitat Mohanty D, Colah RB, Gorakshakar AC, et al. Prevalence of b-thalassemia and other haemoglobinopathies in six cities in India: a multicenter study. J Community Genet. 2013;4:33–42.CrossRefPubMed Mohanty D, Colah RB, Gorakshakar AC, et al. Prevalence of b-thalassemia and other haemoglobinopathies in six cities in India: a multicenter study. J Community Genet. 2013;4:33–42.CrossRefPubMed
4.
5.
Zurück zum Zitat Weatherall DJ. Keynote address: the challenge of thalassemia for the developing countries. Ann N Y Acad Sci. 2005;1054:11–7.CrossRefPubMed Weatherall DJ. Keynote address: the challenge of thalassemia for the developing countries. Ann N Y Acad Sci. 2005;1054:11–7.CrossRefPubMed
6.
Zurück zum Zitat Weatherall DJ. The challenge of haemoglobinopathies in resource-poor countries. Br J Haematol. 2011;154:736–44.CrossRefPubMed Weatherall DJ. The challenge of haemoglobinopathies in resource-poor countries. Br J Haematol. 2011;154:736–44.CrossRefPubMed
7.
Zurück zum Zitat Sangani B, Sukumaran PK, Mahadik C, et al. Thalassaemia in Bombay: the role of medical genetics in developing countries. Bull World Health Organ. 1990;68:75–81.PubMedPubMedCentral Sangani B, Sukumaran PK, Mahadik C, et al. Thalassaemia in Bombay: the role of medical genetics in developing countries. Bull World Health Organ. 1990;68:75–81.PubMedPubMedCentral
8.
Zurück zum Zitat Trehan A, Sharma N, Das R, Bansal D, Marwaha RK. Clinico-investigational and demographic profile of children with thalassemia major. Indian J Hematol Blood Transfus. 2015;31:121–6. Trehan A, Sharma N, Das R, Bansal D, Marwaha RK. Clinico-investigational and demographic profile of children with thalassemia major. Indian J Hematol Blood Transfus. 2015;31:121–6.
9.
Zurück zum Zitat Ware HM, Kwiatkowski JL. Evaluation and treatment of transfusional iron overload in children. Pediatr Clin N Am. 2013;60:1393–406.CrossRef Ware HM, Kwiatkowski JL. Evaluation and treatment of transfusional iron overload in children. Pediatr Clin N Am. 2013;60:1393–406.CrossRef
10.
Zurück zum Zitat Riewpaiboon A, Nuchprayoon I, Torcharus K, Indaratna K, Thavorncharoensap M, Ubol BO. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children. BMC Res Notes. 2010;3:29.CrossRefPubMedPubMedCentral Riewpaiboon A, Nuchprayoon I, Torcharus K, Indaratna K, Thavorncharoensap M, Ubol BO. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children. BMC Res Notes. 2010;3:29.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Ginsberg G, Tulchinsky T, Filon D, Goldfarb A, Abramov L, Rachmilevitz EA. Cost-benefit analysis of a national thalassaemia prevention programme in Israel. J Med Screen. 1998;5:120–6.CrossRefPubMed Ginsberg G, Tulchinsky T, Filon D, Goldfarb A, Abramov L, Rachmilevitz EA. Cost-benefit analysis of a national thalassaemia prevention programme in Israel. J Med Screen. 1998;5:120–6.CrossRefPubMed
12.
Zurück zum Zitat Scalone L, Mantovani LG, Krol M, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin. 2008;24:1905–17.CrossRefPubMed Scalone L, Mantovani LG, Krol M, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin. 2008;24:1905–17.CrossRefPubMed
13.
Zurück zum Zitat Mallik S, Chatterjee C, Mandal PK, Sardar JC, Ghosh P, Manna N. Expenditure to treat thalassaemia: an experience at a tertiary care hospital in India. Iran J Publ Health. 2010;39:78–84. Mallik S, Chatterjee C, Mandal PK, Sardar JC, Ghosh P, Manna N. Expenditure to treat thalassaemia: an experience at a tertiary care hospital in India. Iran J Publ Health. 2010;39:78–84.
14.
Zurück zum Zitat Tamhankar PM, Agarwal S, Arya V, Kumar R, Gupta UR, Agarwal SS. Prevention of homozygous beta thalassemia by premarital screening and prenatal diagnosis in India. Prenat Diagn. 2009;29:83–8.CrossRefPubMed Tamhankar PM, Agarwal S, Arya V, Kumar R, Gupta UR, Agarwal SS. Prevention of homozygous beta thalassemia by premarital screening and prenatal diagnosis in India. Prenat Diagn. 2009;29:83–8.CrossRefPubMed
15.
Zurück zum Zitat Amid A, Saliba AN, Taher AT, Klaassen RJ. Thalassaemia in children: from quality of care to quality of life. Arch Dis Child. 2015;100:1051–7.CrossRefPubMed Amid A, Saliba AN, Taher AT, Klaassen RJ. Thalassaemia in children: from quality of care to quality of life. Arch Dis Child. 2015;100:1051–7.CrossRefPubMed
Metadaten
Titel
Socio-demographic Profile and Economic Burden of Treatment of Transfusion Dependent Thalassemia
verfasst von
Amita Moirangthem
Shubha R. Phadke
Publikationsdatum
09.11.2017
Verlag
Springer India
Erschienen in
Indian Journal of Pediatrics / Ausgabe 2/2018
Print ISSN: 0019-5456
Elektronische ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-017-2478-y

Weitere Artikel der Ausgabe 2/2018

Indian Journal of Pediatrics 2/2018 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.